NASDAQ:ALNA

Allena Pharmaceuticals Competitors

$1.14
-0.06 (-5.00 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.09
Now: $1.14
$1.25
50-Day Range
$1.20
MA: $1.50
$1.81
52-Week Range
$1.07
Now: $1.14
$3.39
Volume1.16 million shs
Average Volume2.08 million shs
Market Capitalization$64.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.39

Competitors

Allena Pharmaceuticals (NASDAQ:ALNA) Vs. CABA, CASI, ADMA, LOGC, GMDA, and GNFT

Should you be buying ALNA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Allena Pharmaceuticals, including Cabaletta Bio (CABA), CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA), LogicBio Therapeutics (LOGC), Gamida Cell (GMDA), and Genfit (GNFT).

Allena Pharmaceuticals (NASDAQ:ALNA) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares Allena Pharmaceuticals and Cabaletta Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allena PharmaceuticalsN/A-207.07%-112.21%
Cabaletta BioN/A-22.99%-22.38%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Allena Pharmaceuticals and Cabaletta Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allena Pharmaceuticals01402.80
Cabaletta Bio00303.00

Allena Pharmaceuticals presently has a consensus target price of $10.40, indicating a potential upside of 812.28%. Cabaletta Bio has a consensus target price of $21.00, indicating a potential upside of 95.35%. Given Allena Pharmaceuticals' higher possible upside, equities research analysts plainly believe Allena Pharmaceuticals is more favorable than Cabaletta Bio.

Risk and Volatility

Allena Pharmaceuticals has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.

Institutional & Insider Ownership

28.0% of Allena Pharmaceuticals shares are held by institutional investors. Comparatively, 68.0% of Cabaletta Bio shares are held by institutional investors. 22.8% of Allena Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Allena Pharmaceuticals and Cabaletta Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allena PharmaceuticalsN/AN/A$-47,340,000.00($2.10)-0.54
Cabaletta BioN/AN/A$-16,940,000.00($4.07)-2.64

Cabaletta Bio is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Allena Pharmaceuticals beats Cabaletta Bio on 6 of the 11 factors compared between the two stocks.

Allena Pharmaceuticals (NASDAQ:ALNA) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

Risk and Volatility

Allena Pharmaceuticals has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Profitability

This table compares Allena Pharmaceuticals and CASI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allena PharmaceuticalsN/A-207.07%-112.21%
CASI Pharmaceuticals-402.87%-60.96%-42.48%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Allena Pharmaceuticals and CASI Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allena Pharmaceuticals01402.80
CASI Pharmaceuticals00103.00

Allena Pharmaceuticals currently has a consensus target price of $10.40, indicating a potential upside of 812.28%. CASI Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 176.24%. Given Allena Pharmaceuticals' higher possible upside, analysts clearly believe Allena Pharmaceuticals is more favorable than CASI Pharmaceuticals.

Earnings and Valuation

This table compares Allena Pharmaceuticals and CASI Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allena PharmaceuticalsN/AN/A$-47,340,000.00($2.10)-0.54
CASI Pharmaceuticals$4.13 million61.27$-46,030,000.00($0.42)-4.31

CASI Pharmaceuticals has higher revenue and earnings than Allena Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

28.0% of Allena Pharmaceuticals shares are held by institutional investors. Comparatively, 32.0% of CASI Pharmaceuticals shares are held by institutional investors. 22.8% of Allena Pharmaceuticals shares are held by company insiders. Comparatively, 24.8% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

CASI Pharmaceuticals beats Allena Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Allena Pharmaceuticals (NASDAQ:ALNA) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

Risk and Volatility

Allena Pharmaceuticals has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500.

Profitability

This table compares Allena Pharmaceuticals and ADMA Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Allena PharmaceuticalsN/A-207.07%-112.21%
ADMA Biologics-166.01%-98.83%-37.21%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Allena Pharmaceuticals and ADMA Biologics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allena Pharmaceuticals01402.80
ADMA Biologics00503.00

Allena Pharmaceuticals currently has a consensus target price of $10.40, indicating a potential upside of 812.28%. ADMA Biologics has a consensus target price of $7.80, indicating a potential upside of 350.87%. Given Allena Pharmaceuticals' higher possible upside, analysts clearly believe Allena Pharmaceuticals is more favorable than ADMA Biologics.

Earnings and Valuation

This table compares Allena Pharmaceuticals and ADMA Biologics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allena PharmaceuticalsN/AN/A$-47,340,000.00($2.10)-0.54
ADMA Biologics$29.35 million7.15$-48,280,000.00($0.92)-1.88

Allena Pharmaceuticals has higher earnings, but lower revenue than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

28.0% of Allena Pharmaceuticals shares are held by institutional investors. Comparatively, 48.9% of ADMA Biologics shares are held by institutional investors. 22.8% of Allena Pharmaceuticals shares are held by company insiders. Comparatively, 11.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ADMA Biologics beats Allena Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

LogicBio Therapeutics (NASDAQ:LOGC) and Allena Pharmaceuticals (NASDAQ:ALNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Earnings & Valuation

This table compares LogicBio Therapeutics and Allena Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-3.49
Allena PharmaceuticalsN/AN/A$-47,340,000.00($2.10)-0.54

LogicBio Therapeutics is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for LogicBio Therapeutics and Allena Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LogicBio Therapeutics00303.00
Allena Pharmaceuticals01402.80

LogicBio Therapeutics currently has a consensus target price of $18.50, indicating a potential upside of 197.43%. Allena Pharmaceuticals has a consensus target price of $10.40, indicating a potential upside of 812.28%. Given Allena Pharmaceuticals' higher probable upside, analysts plainly believe Allena Pharmaceuticals is more favorable than LogicBio Therapeutics.

Institutional & Insider Ownership

33.8% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Allena Pharmaceuticals shares are owned by institutional investors. 23.4% of LogicBio Therapeutics shares are owned by company insiders. Comparatively, 22.8% of Allena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

LogicBio Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500.

Profitability

This table compares LogicBio Therapeutics and Allena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LogicBio TherapeuticsN/A-117.64%-76.85%
Allena PharmaceuticalsN/A-207.07%-112.21%

Summary

LogicBio Therapeutics beats Allena Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Gamida Cell (NASDAQ:GMDA) and Allena Pharmaceuticals (NASDAQ:ALNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Earnings & Valuation

This table compares Gamida Cell and Allena Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gamida CellN/AN/A$-34,350,000.00($1.69)-4.63
Allena PharmaceuticalsN/AN/A$-47,340,000.00($2.10)-0.54

Gamida Cell is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gamida Cell and Allena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gamida CellN/A-112.47%-65.09%
Allena PharmaceuticalsN/A-207.07%-112.21%

Institutional & Insider Ownership

28.0% of Allena Pharmaceuticals shares are owned by institutional investors. 22.8% of Allena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Gamida Cell has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Gamida Cell and Allena Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gamida Cell00503.00
Allena Pharmaceuticals01402.80

Gamida Cell currently has a consensus target price of $20.25, indicating a potential upside of 158.95%. Allena Pharmaceuticals has a consensus target price of $10.40, indicating a potential upside of 812.28%. Given Allena Pharmaceuticals' higher probable upside, analysts plainly believe Allena Pharmaceuticals is more favorable than Gamida Cell.

Summary

Gamida Cell beats Allena Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Genfit (NASDAQ:GNFT) and Allena Pharmaceuticals (NASDAQ:ALNA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Genfit and Allena Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genfit$45.88 million4.04$-72,960,000.00($1.97)-2.24
Allena PharmaceuticalsN/AN/A$-47,340,000.00($2.10)-0.54

Allena Pharmaceuticals has lower revenue, but higher earnings than Genfit. Genfit is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Genfit and Allena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenfitN/AN/AN/A
Allena PharmaceuticalsN/A-207.07%-112.21%

Institutional & Insider Ownership

0.4% of Genfit shares are owned by institutional investors. Comparatively, 28.0% of Allena Pharmaceuticals shares are owned by institutional investors. 22.8% of Allena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Genfit has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Genfit and Allena Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genfit32502.20
Allena Pharmaceuticals01402.80

Genfit currently has a consensus price target of $43.60, indicating a potential upside of 886.43%. Allena Pharmaceuticals has a consensus price target of $10.40, indicating a potential upside of 812.28%. Given Genfit's higher probable upside, analysts plainly believe Genfit is more favorable than Allena Pharmaceuticals.


Allena Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$10.75-4.7%$258.68 millionN/A-7.85
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.81-3.9%$253.03 million$4.13 million-4.02
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.73-0.6%$209.81 million$29.35 million-2.01
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$6.22-7.9%$199.20 millionN/A-3.89
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.82-3.5%$189.40 millionN/A-5.47
Genfit logo
GNFT
Genfit
1.3$4.42-4.8%$185.31 million$45.88 million-2.24Gap Up
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$16.04-5.9%$180.11 millionN/A0.00Increase in Short Interest
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.72-1.5%$177.73 million$104.39 million-2.88
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.04-0.2%$172.72 million$2.45 million-1.90
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.43-0.3%$167.20 millionN/A-7.84
INmune Bio logo
INMB
INmune Bio
1.5$10.77-9.3%$160.83 millionN/A-11.10
Axcella Health logo
AXLA
Axcella Health
1.6$4.26-2.1%$160.56 millionN/A-1.98News Coverage
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$7.06-4.8%$152.62 millionN/A0.00High Trading Volume
Increase in Short Interest
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$7.16-2.2%$151.61 millionN/A-1.83News Coverage
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$8.72-2.6%$151.59 millionN/A-2.72
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.29-2.1%$151.17 million$32.12 million-86.85
Dyadic International logo
DYAI
Dyadic International
1.3$5.09-0.2%$140.25 million$1.68 million-14.97Increase in Short Interest
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.50-2.0%$138.29 million$2.33 million0.00
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.34-1.2%$137.75 million$20,000.000.00News Coverage
Gap Down
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$12.98-0.6%$132.73 millionN/A0.00
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.31-8.2%$123.63 millionN/A-1.59Analyst Report
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$7.81-4.9%$120.89 million$3 million-2.51
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.21-9.7%$114.66 millionN/A-3.06
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.18-1.9%$114.65 million$23.05 million-1.86
PolarityTE logo
PTE
PolarityTE
1.4$0.90-7.7%$109.31 million$5.65 million-0.54Increase in Short Interest
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.18-0.9%$104.73 million$20.92 million-1.25
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.11-1.4%$100.90 million$140,000.000.00
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$9.39-0.0%$68.86 millionN/A0.00Lockup Expiration
BioCardia logo
BCDA
BioCardia
2.0$4.12-0.7%$67.32 million$710,000.00-2.12Increase in Short Interest
Organovo logo
ONVO
Organovo
0.7$8.72-6.0%$62.06 million$2.20 million0.00News Coverage
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.70-7.6%$59.24 million$420,000.00-1.39Increase in Short Interest
GENE
Genetic Technologies
0.4$3.90-4.9%$58.61 million$10,000.000.00
Windtree Therapeutics logo
WINT
Windtree Therapeutics
2.3$2.18-5.5%$57.24 million$200,000.00-0.91Decrease in Short Interest
BBI
Brickell Biotech
1.5$0.84-4.8%$56.22 million$7.92 million-0.35News Coverage
Microbot Medical logo
MBOT
Microbot Medical
1.3$7.72-2.5%$54.87 millionN/A0.00Decrease in Short Interest
News Coverage
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.08-4.6%$45.64 million$1.45 million-0.38Increase in Short Interest
ENTX
Entera Bio
1.2$3.30-0.3%$37.72 million$240,000.00-4.85Decrease in Short Interest
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$3.93-4.3%$37.30 million$192.41 million0.71
BiondVax Pharmaceuticals logo
BVXV
BiondVax Pharmaceuticals
0.5$3.02-12.9%$34.29 millionN/A-1.00Decrease in Short Interest
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$1.42-6.3%$24.56 million$10,000.000.00Increase in Short Interest
Titan Pharmaceuticals logo
TTNP
Titan Pharmaceuticals
1.2$2.29-6.6%$22.59 million$3.61 million-0.31
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.